Today is ##DonorAdvisedFundDay — a new kind of giving day that is redefining how donor-advised funds are used. It’s easier than ever to support our work with a DAF. Your gift helps us fund cutting-edge research and turn scientific discoveries into new cancer treatments faster. Learn more about how you can support us this DAFday: https://lnkd.in/ghSGmv8i
The Mark Foundation for Cancer Research
Research Services
New York, NY 2,163 followers
Partnering with scientists to accelerate transformation in cancer research
About us
The Mark Foundation for Cancer Research actively partners with scientists to accelerate research that will transform the prevention, diagnosis, and treatment of cancer. We fulfill our mission by supporting groundbreaking science carried out by individual investigators, multi-disciplinary teams, and inter-institutional collaborations in the United States and across the globe. Recognizing the obstacles that prevent scientific advances from improving patient outcomes, we maintain a nimble, high-impact approach to funding research through grants for basic and translational cancer research and venture investments in early-stage companies that bridge the gap between bench and bedside.
- Website
-
http://themarkfoundation.org/
External link for The Mark Foundation for Cancer Research
- Industry
- Research Services
- Company size
- 2-10 employees
- Headquarters
- New York, NY
- Type
- Nonprofit
- Founded
- 2015
- Specialties
- cancer research
Locations
-
Primary
New York, NY 10019, US
Employees at The Mark Foundation for Cancer Research
-
Pamela Carroll
Life Science Executive l Entrepreneur l AI-driven Drug Discovery l COO l CBO I R&D Leader
-
Xiaoxiao (Vany) Sun
UCSF Researcher
-
Nicola Mendelsohn CBE
Head of Global Business Group at Meta
-
Ray DuBois
Director: MUSC Hollings Cancer Center, Associate Provost for Cancer Programs at MUSC & Executive Chair of the Mark Foundation for Cancer Research…
Updates
-
Huge congratulations to David Baker, winner of the 2024 Nobel Prize in Chemistry! 🏅 Dr. Baker is a key member of the MATCHMAKERS Cancer Grand Challenges team, which we co-fund with Cancer Research UK (CRUK) and the National Cancer Institute (NCI). As the world’s leading expert in protein design, his expertise is critical to the team’s work developing new tools to predict T cell antigen specificity and pave the way toward more effective and personalized cancer immunotherapies. Dr. Baker is the second member of a Mark Foundation-funded Cancer Grand Challenge team to win a Nobel — Carolyn Bertozzi, a member of the NexTGen team, was awarded the Nobel Prize in Chemistry in 2022. https://lnkd.in/eJKBjHkg
-
Treating cancer requires a multi-pronged approach. Learn how The Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation at the University of Pennsylvania Center, led by Andy Minn, is shifting treatment paradigms with work at the intersection of immunotherapy, immune signaling, and radiation therapy in this excerpt from our 2023 Annual Report. #CancerResearch #Immunotherapy https://lnkd.in/eijQPE4u
-
Could ivonescimab revolutionize the treatment of non-small cell lung cancer? In a recent trial, the bispecific antibody developed by Summit Therapeutics, Inc. outperformed market leader Keytruda. As Mark Foundation CEO Ryan Schoenfeld told BioSpace, these results could be “a really big deal” for patients — potentially sparing many from chemotherapy. While FDA approval will require additional trials, one thing is clear: “The bispecific therapy modality has definitely arrived.” https://lnkd.in/gPnegvBq #NSCLC #lungcancer #immunotherapy
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
biospace.com
-
Open RFP: The Mark Foundation's Drug Discovery Award program is now accepting letters of intent! The Drug Discovery Award offers up to $1 million in funding to help discover and progress a new therapeutic agent into preclinical development. Grantees also receive vital support from seasoned biopharma R&D scientists who will share their expertise on the path to developing a new therapeutic agent. Independent investigators at non-profit research institutions are eligible to apply for funding for projects focused on lead discovery or optimization. Letters of intent are due November 11. Have questions? Mark Foundation CEO Ryan Schoenfeld will hold a webinar for applicants on October 10 at 10 a.m. EDT. Learn more, register for the webinar, and start your proposal: https://lnkd.in/e7Ka8Dz7 #cancerresearch #drugdiscovery #researchfunding
-
The Mark Foundation’s 2023 Annual Report is out! Read it to catch up on our grantees’ remarkable achievements, learn about our ongoing partnerships, and discover how we’re accelerating progress toward cancer prevention, diagnosis & treatment. #CancerResearch https://lnkd.in/dnn3X4jd
-
The data are clear: the risk of more than a dozen cancers is rising among adults under 30. But why are early onset cases becoming more prevalent, and what can we do about it? Mark Foundation Executive Chair Ray DuBois recently joined South Carolina Public Radio to discuss current research & the need for additional funding: https://lnkd.in/eq7xPT3V #colorectalcancer #breastcancer #uterinecancer
-
September is #ChildhoodCancerAwarenessMonth. We’re proud to support scientists fighting pediatric cancer, including Emerging Leader Award winner Paul Northcott, PhD at St. Jude Children's Research Hospital, who is working to identify new treatment targets for brain tumors in children. #EndChildhoodCancer https://lnkd.in/edZFDrqn
-
Many early-career researchers would jump at the chance to join a project with a large team of accomplished scientists — but could that move backfire? As Jonathan Wosen, PhD of STAT highlighted this week, recent research suggests that increasingly large scientific teams can hamper career advancement for early career researchers — potentially contributing to an ongoing exodus from academic research. Part of the problem? Publications by large teams can obscure the contributions of more junior scientists. This challenge is real — but abandoning team science isn’t the answer. Instead, the research community needs new approaches, such as one pioneered by The Mark Foundation with our Endeavor Award program. https://lnkd.in/eSZZUPXX Here’s what makes the Endeavor Awards unique: -We welcome new teams who haven’t worked together previously -We encourage high-risk ideas (& don’t require years of prelim data) -We allow junior scientists to lead research teams Our selection process rewards true team projects: members collaborate on the same question, each contributing unique expertise instead of working separately on similar topics. This encourages mentorship & gives junior scientists greater access to their senior counterparts. Through Endeavor, we’ve seen researchers like Tullia Bruno, Semir Beyaz, Tobias Janowitz, & Rob Welner take on leadership roles, making remarkable strides forward in their careers & meaningful progress on major #cancerresearch challenges. Continued scientific progress requires a strong pipeline of talent. By adapting grant structures and opening up more opportunities for early-career researchers to lead, we can tackle that challenge and benefit from the ideas & insights of scientists at every career stage. What are your thoughts on the rise of large scientific teams and how they impact career development? Let us know in the comments! https://lnkd.in/en_zByAf
Teamwork is good for science — but maybe not for young researchers’ careers
https://www.statnews.com
-
On Monday, we visited The Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation at the University of Pennsylvania to hear the latest from the Center’s director Andy Minn and team members Sara Cherry, Carl June, Costas Koumenis, & E. John Wherry. The Center, founded in 2019, is working to modulate immune signaling pathways for better cancer treatments. Most recently, the team showed that adding JAK inhibitors to anti–PD–1 immunotherapy improves outcomes for patients with non-small cell lung cancer. https://lnkd.in/eUzbqEmi